Medtronic MDT Neuroscience — Selling, general, and administrative expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Medtronic’s 10-K, filed June 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's neuroscience — selling, general, and administrative expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's neuroscience — selling, general, and administrative expense?
- Medtronic (MDT) reported neuroscience — selling, general, and administrative expense of $875M in Q1 2026.
- How has Medtronic's neuroscience — selling, general, and administrative expense changed year-over-year?
- Medtronic's neuroscience — selling, general, and administrative expense increased by 7.6% year-over-year, from $813M to $875M.
- What is the long-term trend for Medtronic's neuroscience — selling, general, and administrative expense?
- Over 3 years (2023 to 2026), Medtronic's neuroscience — selling, general, and administrative expense has grown at a 16.0% compound annual growth rate (CAGR), from $2.19B to $3.42B.
- What does neuroscience — selling, general, and administrative expense mean?
- The cost of selling, marketing, and managing the neuroscience business.
- How do you interpret neuroscience — selling, general, and administrative expense?
- Rising expenses relative to sales may indicate increased competition or higher customer acquisition costs, while lower expenses relative to sales suggest improved operational leverage.
- How does neuroscience — selling, general, and administrative expense compare across companies?
- Comparable to SG&A expense ratios in the medical device sector.